Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3359609 or placebo plus pembrolizumab for first-line PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma
jRCT2080225258Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing GSK3359609 + pembrolizumab with Placebo + pembrolizumab (2 arms). Started Jul 2020; status: completed.
02
Drugs
feladilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080225258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225258.